Patents by Inventor Zaiqi Wang

Zaiqi Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20260048053
    Abstract: The present invention relates to a method for treating a tumor such as a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Application
    Filed: October 23, 2025
    Publication date: February 19, 2026
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang, Xuebin Liu
  • PHARMACEUTICAL COMBINATION FOR TREATING TUMORS AND USE THEREOF
    Publication number: 20250099450
    Abstract: An FAK inhibitor, an MEK inhibitor, and an immune checkpoint inhibitor are used in combination to treat tumors, and an FAK inhibitor and an MEK inhibitor are used in combination to treat tumors.
    Type: Application
    Filed: January 18, 2023
    Publication date: March 27, 2025
    Inventors: Baoyuan Zhang, Xuebin Liu, Zaiqi Wang
  • Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
    Patent number: 12257251
    Abstract: A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 11, 2023
    Date of Patent: March 25, 2025
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang
  • PHARMACEUTICAL COMPOSITION FOR TREATING TUMORS AND USE
    Publication number: 20250049828
    Abstract: The present invention relates to a combination of an FAK inhibitor, an anthracycline chemotherapeutic drug, and an immune checkpoint inhibitor to treat tumors. The present invention also relates to a combination of an FAK inhibitor and an anthracycline chemotherapeutic drug to treat tumors.
    Type: Application
    Filed: December 8, 2022
    Publication date: February 13, 2025
    Inventors: Baoyuan Zhang, Xuebin Liu, Zaiqi Wang
  • Use of BI853520 in cancer treatment
    Patent number: 12121519
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: October 22, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • Combined use of IN10018 and PLD
    Patent number: 12115160
    Abstract: The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
    Type: Grant
    Filed: August 24, 2023
    Date of Patent: October 15, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Jun Jiang, Shuang Xie, Jiangwei Zhang, Zaiqi Wang
  • Combination of BI853520 with chemotherapeutic drugs
    Patent number: 12097200
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: September 24, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang
  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20240307395
    Abstract: The present invention relates to a method for treating a tumor such as a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 19, 2024
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang, Xuebin Liu
  • DRUG COMBINATION OF FAK INHIBITOR AND IMMUNOGENIC CELL DEATH INDUCER AND USE THEREOF
    Publication number: 20240285627
    Abstract: The present disclosure relates to a combination of an FAK inhibitor, an immunogenic cell death inducer, and an immune checkpoint inhibitor for the treatment of a tumor. The present disclosure also relates to a combination of an FAK inhibitor and an immunogenic cell death inducer for the treatment of a tumor.
    Type: Application
    Filed: April 4, 2024
    Publication date: August 29, 2024
    Inventors: Baoyuan Zhang, Xuebi Liu, Ping Zhang, Ran Pang, Zaiqi Wang
  • Use of BI853520 in cancer treatment
    Patent number: 12064431
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is used, which can be administered alone or in combination with a KRAS inhibitor and/or an MEK inhibitor.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: August 20, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • Use of BI853520 in cancer treatment
    Patent number: 12059421
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: August 13, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
    Publication number: 20240261285
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Application
    Filed: April 11, 2024
    Publication date: August 8, 2024
    Inventors: Zaiqi Wang, Jiangwei Zhang
  • Solid form of compound
    Patent number: 11999719
    Abstract: Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.
    Type: Grant
    Filed: July 5, 2023
    Date of Patent: June 4, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Zaiqi Wang, Jing Gao, Yingxia Sang
  • Drug combination and use for treating tumors
    Patent number: 11986477
    Abstract: The present disclosure relates to the combination of IN10018 and an epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of tumors.
    Type: Grant
    Filed: November 6, 2023
    Date of Patent: May 21, 2024
    Assignee: INXMED (NANJING) CO., LTD.
    Inventors: Baoyuan Zhang, Xuebin Liu, Jiaming Gao, Ping Zhang, Ran Pang, Zaiqi Wang
  • DRUG COMBINATION AND USE FOR TREATING TUMORS
    Publication number: 20240082247
    Abstract: The present disclosure relates to the combination of IN10018 and an epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of tumors.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 14, 2024
    Inventors: Baoyuan Zhang, Xuebin Liu, Jiaming Gao, Ping Zhang, Ran Pang, Zaiqi Wang
  • SOLID FORM OF COMPOUND
    Publication number: 20240051942
    Abstract: Provided is a solid form of a compound of formula (I) or a salt thereof, or a solvate thereof, or a solvate of a salt thereof, or a mixture thereof.
    Type: Application
    Filed: July 5, 2023
    Publication date: February 15, 2024
    Inventors: Zaiqi Wang, Jing Gao, Yingxia Sang
  • COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS
    Publication number: 20240024319
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 25, 2024
    Inventors: Zaiqi Wang, Jiangwei Zhang
  • COMBINED USE OF IN10018 AND PLD
    Publication number: 20230390289
    Abstract: The present invention relates to the combined use of: (a) the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) PLD or a pharmaceutically acceptable salt thereof, for treating ovarian cancer.
    Type: Application
    Filed: August 24, 2023
    Publication date: December 7, 2023
    Inventors: Jun Jiang, Shuang Xie, Jiangwei Zhang, Zaiqi Wang
  • USE OF BI853520 IN CANCER TREATMENT
    Publication number: 20230372340
    Abstract: The present invention relates to a method for treating a tumor with a KRAS mutation. In the method, a compound 2-fluoro-5-methoxy-4-[(4-(2-methyl-3-oxo-2,3-dihydro-1H-isoindole-4-oxy)-5-trifluoromethyl-pyrimidine-2-yl)amino]-N-(1-methyl-piperidine-4-yl)benzamide or a pharmaceutically acceptable salt thereof is administered in combination with a KRAS inhibitor or an MEK inhibitor.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 23, 2023
    Inventors: Zaiqi Wang, Jiangwei Zhang, Jun Jiang, Baoyuan Zhang
  • USE OF FAK INHIBITOR IN PREPARATION OF DRUG FOR TREATING TUMORS HAVING NRAS MUTATION
    Publication number: 20230364088
    Abstract: A use of a FAK inhibitor in the preparation of a drug for preventing and/or treating tumors having an NRAS mutation. A method for treating tumors that have experienced an NRAS mutation, which comprises administering an effective dose of a FAK inhibitor to an individual. A FAK inhibitor for treating tumors having an NRAS mutation. The FAK inhibitor is B1853520, defactinib, GSK2256098, PF-00562271, VS-4718 or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 11, 2023
    Publication date: November 16, 2023
    Inventors: Zaiqi WANG, Jiangwei ZHANG, Jun JIANG